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Dimethyl sulfoxide (DMSO) is routine- 
ly used to prevent freeze- thaw-induced 
damage to a variety of biological systems. 
In that context, relatively high drug con- 
centrations in excess of one molar are usu- 
ally used. However, lower concentrations 
of the drug produce many pharmacological 
effects (26) which may be efficacious for 
reducing hypoxia- or ischemia-induced cell 
damage which is often encountered during 
organ preservation protocols that do not 
necessarily involve freezing. 
During the course of a study of several 
interventions which might be useful to pre- 
vent damage to the globally ischemic heart, 
we observed a relatively discrete but 
perhaps important action of dimethyl sulf- 
oxide. When added to hypothermic cardio- 
plegic solutions, 70 mM dimethyl sulfoxide 
significantly and consistently prevented 
alterations of mitochondrial oxidative phos- 
phorylating activity after 2 hr of global 
ischemia and reperfusion. Based on these 
findings, the known pharmacological spec- 
trum of action of dimethyl sulfoxide, and 
a postulated mechanism by which it exerted 
its protective effects, we were led to spec- 
ulate that the drug might have more wide- 
spread applicability to organ preservation 
than it currently enjoys. 
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MATERIALS AND METHODS 
Model of Curdiac Globul Ischemia 
We used hearts isolated from healthy 
New Zealand rabbits weighing approxi- 
mately 1 kg. The rabbit was stunned by a 
blow to the head, exsanguinated, and the 
thorax was opened. The heart and lungs 
were quickly removed and the ascending 
aorta was cannulated with a blunted 12- 
gauge needle. The cannula was quickly 
mounted on a nonrecirculating nonpulsatile 
perfusion circuit, and retrograde aortic 
perfusion with an oxygenated normother- 
mic (37°C) physiological saline solution 
(PSS; see below) was begun. A polyethyl- 
ene catheter was tied into the pulmonary 
artery for collecting and measuring coro- 
nary effluent and lactate dehydrogenase 
(LDH) released into it. The lungs were re- 
moved once perfusion was established, and 
the remaining pulmonary vessels were li- 
gated. A saline-filled, balloon-tipped cath- 
eter connected to a Statham pressure trans- 
ducer was inserted through a left atriot- 
omy into the left ventricular chamber to 
measure left ventricular developed pressure 
(LVDP) and its first derivative, LV dP/dt. 
A saline-filled calibrated syringe connected 
by stopcock to the catheter was used to 
vary the volume of the intraventricular 
balloon. A thermostated water jacket was 
raised around the heart. The hearts were 
allowed to beat spontaneously, and during 
both preischemic and postischemic perfu- 
sion with oxygenated PSS perfusion pres- 
sure was maintained at 75 mm Hg by ad- 
justing the speed of the perfusion pump. We 
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recorded LVDP, LV dPldt, perfusion pres- 
sure, and the isolated heart electrogram on 
an oscillograph throughout the experiment. 
All hearts received an initial 30-min equili- 
bration perfusion with oxygenated PSS at 
37”C, and then preischemic functional indi- 
cators described below were recorded. 
Hearts were then assigned randomly to one 
of the experimental or control (nonisch- 
emit) groups. 
Most hearts were made globally isch- 
emit. After equilibration they were per- 
fused for 5 min with one of two hypoxic 
(nonoxygenated) substrate-free hypother- 
mic (20 or 27°C) cardioplegic test solutions, 
then made ischemic by terminating perfu- 
sion. The thermostated jacket surrounding 
the heart was tilled with the same test solu- 
tion, at the same temperature, as that which 
had been perfused. This was done to pre- 
vent desiccation and to maintain tempera- 
ture during the long perfusion-free period. 
Hypothermic temperatures were regulated 
with a Haake refrigerated circulator. At the 
end of a 2-hr uninterrupted period of global 
ischemia the jacket was drained and a sec- 
ond 5-min perfusion with the identical test 
solution was begun. The hearts were then 
reperfused for 60 min with the normother- 
mic oxygenated PSS as was used during 
preischemic equilibration. The brief post- 
ischemic reperfusion with cardioplegic solu- 
tion was predicated upon the assumption 
that it would be preferable to wash out any 
toxic metabolites which might have ac- 
cumulated in the extracellular spaces dur- 
ing ischemia, and before providing the heart 
with a more physiological, oxygenated so- 
lution which was conducive to contraction. 
Additionally, in some intraoperative set- 
tings the heart is briefly reperfused with 
cardioplegic solution before reperfusing it 
with blood from the cardiopulmonary 
bypass circuit after ischemia, primarily for 
the reason noted above. 
Postischemic recovery of function was 
considered to be that which we measured at 
the end of the entire 65min reperfusion pe- 
riod (5 min with cardioplegic solution and 
60 min with oxygenated PSS). 
Five hearts were not made ischemic, but 
instead were perfused for 220 min with ox- 
ygenated PSS at 37°C. Function was mea- 
sured after the 30-min equilibration period 
and again 190 min later. This last measure- 
ment coincided with the time at which 
postischemic function was measured in 
hearts which had been made ischemic. The 
nonischemic hearts therefore served as 
controls. 
The major indicators of cardiac status 
which we measured were spontaneous 
heart rate, coronary flow (which was in- 
versely proportional to coronary vascular 
resistance, since flow always was measured 
at the same perfusion pressure, 75 mm Hg), 
LDH release in the pulmonary artery 
effluent, and LVDP and dP/dt. These latter 
measurements of ventricular contractility 
were assembled as LV function (Starling) 
curves: LVDP was measured at various LV 
end-diastolic pressures which were, in turn, 
a function of LV volume. LV volume was 
varied experimentally by incrementally in- 
creasing the volume of the saline-filled in- 
traventricular balloon (33). The function 
curves were constructed after the 30-min 
equilibration period and again after 65 min 
of reperfusion. At all other times, balloon 
volumes were adjusted to give an end- 
diastolic pressure of approximately 5 mm Hg. 
Mitochondrim 
Once postreperfusion functional mea- 
surements were made the heart was re- 
moved from the perfusion circuit and mito- 
chondria were isolated from left ventricular 
and septal myocardium (32) by differential 
centrifugation, in a medium containing KC1 
(0.18 M), Tris-EDTA (10 mM, pH 7.40, at 
4°C) and bovine serum albumin (0.5%, 
w/v). The respiratory and phosphorylating 
activity of these organelles were evalu- 
ated polarographically (Gilson Oxygraph 
equipped with a Clark-type electrode). De- 
tails of the isolation protocol are described 
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elsewhere (32). For convenience the com- 
position of the media used for assaying mi- 
tochondrial function, and details of the 
assay conditions, are given in Table 2, in 
which the pertinent experimental data are 
summarized. 
In some experiments we tested the direct 
effects of dimethyl sulfoxide on the func- 
tion of mitochondria isolated from nonisch- 
emit-nonperfused rabbit hearts. For these 
experiments we used a vibrating platinum 
electrode, since preliminary studies showed 
that high dimethyl sulfoxide concentra- 
tions (0.42 M or more) caused the Clark 
electrode to respond erratically, even when 
mitochondria were not present in the assay 
cuvette. Presumably this was due to an 
effect of the drug on the permeability or 
electrical properties of the Clark elec- 
trode’s Teflon membrane. 
Perfusutes and Chemicals 
The composition of the standard oxygen- 
ated perfusate (PSS) was (mM): NaCl, 118; 
KCl, 5.4; MgClz, 1.2; NaHC03, 25; 
KH2P0+, 1; CaCl,, 2.4; and D-glucose, 10. 
The solution had a pH of 7.40 after equili- 
bration with a mixture of 95% 0, and 5% 
Cq. All hearts were perfused with this so- 
lution during the 30-min preischemic equili- 
bration and again during the last 60 min of 
postischemic reperfusion; nonischemic 
controls were perfused exclusively with 
this solution. 
The test solution perfused briefly before 
and after ischemia was a procaine-free 
modification of the St. Thomas’ Hospital 
Solution described by Jynge and colleagues 
(17). It contained (mM): NaCl, 92; KCl, 15; 
MgCL, 15; NaHCO,, 25; KH2P04, 1; and 
CaCl,, 1.2. It was used in the hypoxic state 
and had a pH of 7.70. 
Solutions containing dimethyl sulfoxide 
(experimental drug grade; Crown Zeller- 
bath Corporation, Camas, Wash.) were 
made by replacing appropriate volumes of 
water with pure drug (28). 
RESULTS 
Figure 1 shows left ventricular developed 
pressures, measured at various end- 
diastolic pressures, for hearts in the non- 
ischemic control and ischemic-reperfused 
groups. The data show that 2 hr of global 
ischemia plus reperfusion caused the ex- 
pected decreases of postischemic contrac- 
tile function, compared to function mea- 
sured before ischemia or in the nonischemic 
controls; that cardioplegia at 20°C provided 
significantly better preservation of pressure 
development than at 27°C; and that sup- 
plementing cardioplegia solution with 70 
mM dimethyl sulfoxide produced no addi- 
tional effects, beneficial or deleterious, 
compared to the appropriate drug-free so- 
lution. Measurements of maximum rates of 
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FIG. 1. Left ventricular developed pressure is plot- 
ted as a function of left ventricular end-diastolic pres- 
sure, which was adjusted by varying the volume of a 
left intraventricular balloon. Prolonged perfusion of 
nonischemic hearts resulted in a slight decrease of left 
ventricular function, compared to values measured 
before ischemia (preischemic values). Maximum left 
ventricular developed pressure after 2 hr global isch- 
emia and 1 hr was significantly greater in hearts made 
ischemic at 20 than at 27°C. For a given temperature 
during ischemia, however, adding 70 mA4 dimethyl 
sulfoxide (DMSO) to the cardioplegic solution (CS) 
had no consistent or significant effect on postischemic 
contractile function. 
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(dP/dr, Table 1) or left ventricular com- 
pliance (left ventricular end-diastolic pres- 
sure as a function of end-diastolic volume) 
showed the same between-group relation- 
ships (data not presented). 
Table 1 summarizes values for heart rate, 
coronary flow, lactate dehydrogenase re- 
lease, and tissue Ca content. The major 
pertinent observation was that supple- 
menting CS with 70 mM dimethyl sulfoxide 
had no significant effect on any of these 
variables. 
Table 2 summarizes the in vitro respira- 
tory activity of mitochondria isolated from 
hearts in the various groups. Glutamate 
plus malate were the respiratory substrates. 
There are three major effects seen in these 
data. First, perfusing hearts for 3.5 hr with 
a normothermic, colloid-free solution 
markedly reduces State 3 (ADP-stimulated) 
respiratory rates and the respiratory control 
ratio (RCR) and oxidative phosphorylation 
rate (OPR), two functional indicators which 
are based, in part, on the State 3 respiratory 
rate. This effect is seen by examining val- 
ues reported for nonperfused heart mito- 
chondria. Next, the data show that perfus- 
ing hearts with CS at either 27 or 2O”C, and 
making them globally ischemic at those 
temperatures, results in further and gener- 
ally significant decreases of State 3 rates, 
RCR and OPR, compared to the appropri- 
ate control, namely those values for the 
nonischemic control group. Finally, and 
perhaps most important, the data show that 
supplementing hypothermic CS with 70 mM 
dimethyl sulfoxide increased State 3 respi- 
ratory rates to values which were not sig- 
nificantly different from those of nonisch- 
emit control mitochondria, but were sig- 
nificantly greater than those measured in 
the appropriate drug-free CS-treated group. 
Increasing State 3 respiratory rates also in- 
creased RCR and OPR values. Based on 
analysis of variance, we found no between- 
group differences of mitochondrial ADP:O 
ratios; however, this functional indicator 
is relatively resistant to all but the most 
severe ischemic insults, and is considered 
to be a relatively insensitive index of mi- 
tochondrial integrity. 
Table 3 summarizes the direct effects of 
0.14 to 1.4 M (1 to lo%, v/v) dimethyl sulf- 
oxide on mitochondrial respiratory control 
and oxidative phosphorylation rates. The 
only significant effect produced by the drug 
was at 1.4 M, manifest as a decrease of the 
respiratory control ratio, due to decreased 
State 3 respiratory rates. 
DISCUSSION 
Our results emanated from a larger study 
designed to improve upon myocardial pres- 
ervation during induced intraoperative 
ischemia, afforded by the clinical standard, 
hypothermic cardioplegia. It was predicated 
upon growing evidence that reoxygenation 
of ischemic (and, therefore hypoxic or 
anoxic) organs causes the generation or ex- 
cessive accumulation of cytotoxic oxygen 
metabolites (superoxide anion; hydroxyl 
radical; hydrogen peroxide), presumably 
due to depletion of cellular enzymes which 
normally and rapidly convert these metab- 
olites to less toxic products. Mitochondria 
appear to be an important site for the gen- 
eration of these metabolites (2, 8, 20, 21), 
some of which are free radicals, and so it is 
likely that one of the important targets of 
the cytotoxicity would be the mitochondria 
themselves. 
In our study we found that the effects of 
70 m&Z dimethyl sulfoxide were limited to 
improvements of mitochondrial oxidative 
phosphorylating activity. The drug did not 
significantly alter other indicators of car- 
diac function, the most important of which 
are ventricular pressure development and 
compliance. However, perhaps a more rel- 
evant observation is that although higher 
concentrations of the drug can be cardio- 
toxic (11, 28), and lower concentrations 
can exacerbate cell damage caused by path- 
ological states (lo), we observed no adverse 
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TABLE 2 
Respiratory Function” of Mitochondria Isolated from Nonischemic or Ischemic-Reperfused Hearts 
Respiratory rates 
Group N State 3b State 4b RCRb ADP:O ratio OPRb 
Nonperfused 6 174 2 32 13 * 3 14.0 * 0.7 2.58 + 0.06 448 + 89 
Nonischemic 
control 5 109 * 14 * 11 1 9.9 0.5 2.54 zt 0.02 271 2 k 36 
Ischemic 
27°C CS’ 7 68 L 7* lot 1 6.7 ? 0.4” 2.46 2 0.02 165 + 15* 
27”C, CS + 
dimethyl sulfoxide 6 104 2 12** 12 ” 1 8.5 t 0.4”* 2.63 -c 0.09 273 2 30** 
20°C cs 6 89 k 9 lo? 1 8.7 + 0.7 2.47 * 0.06 220 k 21 
2o”c, cs + 
dimethyl sulfoxide 6 123 2 18** 16 ? 2* 8.2 -?r 0.9 2.40 k 0.12 295 + 44** 
a Values shown are arithmetic means & 1 SEM. Mitochondrial function was assayed in a medium containing 
220 mM 4.4 mM sucrose, K,HPO,, 7.5 mM Tris-glutamate, 7.5 mM Tris-malate, approximately 1 mg/ml 
mitochondrial protein, 500 nmol Na,-ADP, in 13 mM morpholinopropanesulfonic acid buffer, pH 7.40, at 30°C. 
Total assay volume was 1.605 ml. A Gilson Oxygraph with Clark-type oxygen electrode was used. 
b Respiratory rates are reported as natom O/min/mg protein. RCR, Respiratory control ratio (State 3 rate/ 
State 4 rate). OPR, Oxidative phosphorylation rate (State 3 rate x ADP:O ratio). 
c CS, potassium- plus magnesium-enriched cardioplegia solution. Dimethyl sulfoxide was 70 mM. 
* Significantly different (P < 0.05) from nonischemic control value, based on nonpaired t test. 
** Significantly different (P < 0.05) from comparable drug-free group, based on nonpaired t test. 
TABLE 3 
Direct Effects of Dimethyl Sulfoxide on Respiratory 
Control Ratios and Oxidative Phosphorylation 
Rates of Normal Rabbit Heart Mitochondria” 
Dimethyl 
sulfoxide (M) RCRb OPR” 
0 100% 100% 
0.14 16 2 8 325 
0.42 -525 426 
0.84 -1212 4*4 
1.41 -29 f  8* -5-c4 
n Three to five preparations were studied. Mito- 
chondria were isolated from nonperfused hearts. Con- 
trol values and experimental conditions are noted in 
Table 2. Incubation medium was made by replacing 
appropriate volumes of water with drug-grade dimethyl 
sulfoxide . 
b Values given are arithmetic means & SEM, and 
are expressed as a percentage of the value obtained in 
dimethyl sulfoxide-free medium (which was normalized 
to 100%). RCR, Respiratory control ratio (State 3 rate 
of oxygen consumption/subsequent State 4 rate); OPR, 
oxidative phosphorylation rate (State 3 rate x ac- 
companying ADPO ratio). 
* Significantly different (P < 0.05, paired r test) 
from drug-free control. 
the experimental conditions we imposed 
and on the measurements we made. 
Dimethyl sulfoxide produces many 
pharmacological effects which are relevant 
to organ preservation in general (27), and to 
myocardial preservation in particular (27, 
29). It can alter the activity of a variety of 
enzymes (3, 18, 26, 27, 30), and can have 
direct effects on mitochondria (5, 6). How- 
ever, the circumstantial evidence which 
best supports a putative mechanism for the 
protective action of dimethyl sulfoxide 
seems to center on its effects on “reoxy- 
genation-mediated” damage (14). 
Finney and colleagues (12) reported that 
dimethyl sulfoxide, combined with hydro- 
gen peroxide, lessened myocardial infarct 
size in porcine hearts subjected to coronary 
artery ligation in situ. Leon and colleagues 
(19) also demonstrated that chronic di- 
methyl sulfoxide pretreatment lessened the 
severity of isoproterenol-induced myocar- 
dial necrosis and prevented ventricular 
aneurysm development. High-dose isopro- 
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terenol treatment is thought to produce a 
relative myocardial ischemia due to drug- 
induced increases of oxygen demand in 
great excess of oxygensupply. Both Finney 
and Leon speculated that dimethyl sulf- 
oxide protected by increasing oxygen de- 
livery to ischemic tissue, as has been re- 
ported to occur with normal tissues (23). 
However, these observations do not ap- 
pear to be mechanistically consistent with 
the growing evidence about reoxygenation- 
mediated cell damage, or some of the ex- 
perimental data concerning ways to re- 
duce that component of damage. For ex- 
ample, gradual reoxygenation delays the 
onset of reoxygenation-mediated dam- 
age, and so enhanced cellular oxygen deliv- 
ery, particularly in combination with hy- 
drogen peroxide, one of the implicated 
toxic oxygen metabolites, would not be ex- 
pected to lessen damage. Also, administra- 
tion of mitochondrial poisons such as CN-, 
which inhibits mitochondrial electron trans- 
port and, presumably, mitochondrial oxy- 
gen metabolite generation, prevents the de- 
velopment of irreversible mitochondrial 
damage and other manifestations of re- 
oxygenation damage (13) which lead to 
myocardial cell death. Therefore, an inter- 
vention which simply enhances cell oxygen 
tensions upon reperfusion would either en- 
hance oxygen-mediated damage, hasten its 
onset, or both. 
The role of free-radical formation and 
membrane lipid peroxidation by free radi- 
cals as a component of oxygen metabolite- 
related pathology, is well established (7, 25, 
34). Of relevance to this study, then, are the 
observations that dimethyl sulfoxide is a 
free-radical scavenger. This property has 
been cited as a primary mechanism by 
which the drug protects against radiation- 
induced damage Cl), prevents the diabe- 
togenic effects of alloxan (15), inhibits 
some hepatic microsomal enzymes (4), and 
inhibits prostaglandin biosynthesis (9, 16, 
23). Inhibition of prostaglandin biosyn- 
thesis and scavenging of free radicals prob- 
ably explain the drug’s ability to inhibit 
platelet aggregation and inflammation. 
Therefore, we speculate that since mito- 
chondria generate free radicals, and since 
dimethyl sulfoxide can scavenge these, this 
constitutes a reasonable mechanism for its 
discrete but significant effects. To support 
this, we have found (30) that superoxide 
dismutase and catalase, enzymes known to 
convert cytotoxic oxygen metabolites to 
less toxic products, also enhance the pro- 
tective effects of cold cardioplegia solu- 
tions, and produce, among other actions, 
preservation of mitochondrial function after 
global ischemia and reperfusion. We have 
not measured lipid peroxide levels in our 
ischemic-reperfused hearts to establish de- 
finitively the proposed mechanism of ac- 
tion, however. 
The major clinical criteria used to assess 
postischemic cardiac status center on the 
ability of the heart to contract sufficiently 
to maintain cardiac output, not on mito- 
chondrial function. This may appear to di- 
minish the importance of our data, which 
showed improvements only of mitochon- 
drial function. However, postoperative 
cardiac support frequently involves ino- 
tropic drugs which concomitantly increase 
myocardial oxygen demand. Therefore, 
although basal postischemic mitochon- 
drial function may be adequate for the hy- 
podynamic heart with its lower oxygen 
demands, peak (stimulated) oxidative 
phosphorylating capacity may be inade- 
quate when an inotropic drug is adminis- 
tered, or when adrenergic influences to the 
heart are increased. Therefore, the ability 
of dimethyl sulfoxide to maintain mito- 
chondrial function may take on added im- 
portance, despite its negligible effect on 
contractile performance. 
We raise the question of whether di- 
methyl sulfoxide may have more wide- 
spread use than it currently has. Post- 
hypoxic or postischemic reoxygen-me- 
diated damage occurs in the heart and brain 
(22), and it is likely to be a universal phe- 
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nomenon, applicable to other organs such 
as the kidney. Ischemia and hypoxia of 
varying intensity and duration are com- 
mon accompaniments of virtually all organ 
preservation protocols, regardless of 
whether the organ will be perfused continu- 
ously, stored in an ischemic state after an 
initial flush, or frozen and thawed. We 
suggest then that since dimethyl sulfoxide 
can confer some additional protection, does 
so at concentrations which appear to be in- 
nocuous, and are far below those poten- 
tially toxic concentrations which are con- 
sidered to be cryoprotective, further study 
is warranted, particularly in view of the di- 
verse pharmacological effects of the drug 
which have heretofore been largely ig- 
nored. 
SUMMARY 
Isolated perfused rabbit hearts were 
made globally ischemic for 2 hr, then re- 
perfused. For 5 min before and after isch- 
emia hearts were perfused with hypother- 
mic (20 or 27”C), hypoxic, substrate-free 
cardioplegic solutions, some of which con- 
tained 70 mM dimethyl sulfoxide. Post- 
ischemic ventricular pressure development, 
spontaneous heart rate, coronary flow, 
lactate dehydrogenase release, tissue Ca2+ 
content, and in vitro mitochondrial oxida- 
tive phosphorylation were used to eval- 
uate the protective effects of the various 
solutions. Aside from the expected ob- 
servations that cold cardioplegia lessens 
ischemic damage, we found that dimethyl 
sulfoxide gave no indication that it exacer- 
bated ischemic damage or lessened the 
protection afforded by cardioplegia. We 
also found that, compared to values mea- 
sured in comparable drug-free treated 
hearts, dimethyl sulfoxide significantly im- 
proved mitochondrial State 3 respiratory 
rates, respiratory control, and oxidative 
phosphorylation rates, and essentially pre- 
vented mitochondrial changes due to isch- 
emia and reperfusion. We propose that di- 
methyl sulfoxide may act as a “scavenger” 
of cytotoxic free radicals, many of which 
are known to be generated by mitochondria 
during reoxygenation. Since hypoxia, isch- 
emia, and reoxygenation are common ac- 
companiments of most organ preservation 
protocols, we suggest that low concentra- 
tions of dimethyl sulfoxide might serve as a 
useful adjunct to organ preservation in the 
nonfrozen state, when cryoprotective con- 
centrations are not needed. 
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